Clinical Trial Update: SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2, Phase 3]

View source ↗

Summary

SC1011 is being studied in a Phase 2/Phase 3 trial for idiopathic pulmonary fibrosis, with recruiting status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• SC1011

Snippet

Sponsor: Guangzhou JOYO Pharma Co., Ltd | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2, Phase 3 | Status: RECRUITING